Cargando…
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficult...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897065/ https://www.ncbi.nlm.nih.gov/pubmed/31819577 http://dx.doi.org/10.2147/DMSO.S229802 |